Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health Registry


Drug development is an expensive process that is marked by a high-failure rate. For this reason early stage bioequivalence and pharmacokinetic studies are essential in determining the fate of new drug products. In this study, we sought to systematically assess the current trends of ongoing and recently completed bioequivalence and bioavailability trials… (More)


3 Figures and Tables